ASPH / Aspartyl/asparaginyl beta-hydroxylase · IHC design guide

Design Immunohistochemistry for ASPH

Plan ASPH staining in paraffin sections using the catalog antibody at 0.5–1 μg/ml (datasheet PB9478). Compare the cytoplasmic pattern with HPA tissue IHC while accounting for its uncertain reliability (HPA tissue IHC).

Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use

Immunohistochemistry protocol sheet for ASPH (IHC for ASPH): expected localisation General cytoplasmic tissue staining (HPA tissue IHC), antibody PB9478, validated IHC image, and IHC protocol steps — Printable **ASPH** IHC protocol sheet — expected localisation General cytoplasmic tissue staining (HPA tissue IHC), antibody PB9478, controls and protocol steps. Open the full ASPH IHC guide →

Navigate to: Protocols Staining pattern Controls Antibodies

ASPH Immunohistochemistry Experimental Design Guide

Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before staining

	Expected localisation	General cytoplasmic tissue staining (HPA tissue IHC)
	Staining pattern	High in adipocytes; generally cytoplasmic (HPA tissue IHC)
	Antigen retrieval	Citrate pH 6 HIER, heat-mediated (datasheet PB9478)
	Positive control ⓘ	Adipose tissue+4 more · see all
	Negative control ⓘ	Heart muscle+4 more · see all

Important caveats

Reasons your staining may differ from the expected pattern.

	Fixation	Keep fixation consistent across paraffin sections. (standard IHC practice; not target-specific)
	Caveat	Staining and RNA show only medium consistency (HPA tissue IHC)
	Regulation	Isoform expression varies by tissue (UniProt)
	Isoform / epitope	11 isoforms; check the epitope against cytoplasmic 1–53 and lumenal 75–758 (UniProt)

Section 1

Recommended ASPH IHC & IF Protocols

The catalog antibody’s IHC-P protocol is paired with a published ASPH protocol using breast cancer and adjacent normal tissue sections (PMC7784592).

Recommended immunohistochemistry (IHC-P) protocol parameters
Sample	Paraffin-embedded Human Mammary Cancer tissue; fixative not specified (datasheet PB9478)
Fixation	Image fixative and duration unreported (datasheet PB9478); verify before use.
Sectioning	4–5 µm sections on charged slides (standard)
Deparaffinisation	Xylene, graded ethanol series to water (standard)
Antigen retrieval	Heat retrieval: Citrate pH 6, 20 min (datasheet PB9478)
Peroxidase block	3% H2O2, 10 min, room temperature (standard)
Blocking	10% goat serum (datasheet PB9478)
Primary antibody	Rabbit anti-ASPH, 0.5-1μg/ml (datasheet PB9478)
Primary incubation	Overnight at 4 °C (datasheet PB9478)
Detection	Streptavidin-biotin complex (SABC), DAB chromogen (datasheet PB9478)
Counterstain	Hematoxylin, blue, dehydrate and mount (standard)
Expected result	ASPH-positive staining in adipocytes of adipose tissue (HPA tissue IHC: High). HPA tissue profile: General cytoplasmic expression. No signal in the no-primary control.

💡Decision noteStart with heat-mediated citrate pH 6 retrieval for the catalog antibody (datasheet PB9478); the published breast tissue excerpt does not specify retrieval (PMC7784592).

Section 2

What Is the Expected ASPH Staining Pattern?

ASPH is an endoplasmic reticulum (ER) and sarcoplasmic reticulum membrane protein, with residues 1–53 cytoplasmic and 75–758 lumenal (UniProt Q12797 topology). In paraffin-section IHC, expect mainly cytoplasmic staining: HPA reports high staining in adipocytes, respiratory epithelial cells, and several glandular and neural cell populations (HPA tissue IHC). Treat the tissue pattern cautiously because HPA rates its IHC reliability Uncertain, with medium agreement between antibody staining and RNA data (HPA tissue IHC).

What am I looking at on my slide?
Granular or reticular cytoplasmic staining in adipocytes or bronchial respiratory epithelial cells.	This fits an intracellular membrane protein and HPA’s high staining in those cell types (UniProt Q12797 subcellular location; HPA tissue IHC). In chromogenic IHC, judge the cellular distribution against neighboring tissue and controls; an ER-compatible appearance alone does not establish antibody specificity (general IHC practice).
A crisp nuclear-only, extracellular, or continuous cell-surface pattern dominates the section.	That distribution conflicts with the reported ER and sarcoplasmic reticulum membrane locations (UniProt Q12797 subcellular location). Review controls, detection chemistry, and antibody validation before calling it ASPH; morphology alone cannot identify the cause (general IHC practice).
Strong staining appears in cardiomyocytes, germinal center cells, or skeletal myocytes.	HPA reports these cells as not detected by tissue IHC (HPA tissue IHC). Consider cross-reactivity or endogenous detection activity, and compare with an appropriate negative reagent control (general IHC practice). These HPA observations are antibody-dependent, not proof that every isoform is absent (UniProt Q12797 isoforms; HPA tissue IHC).
Broad, diffuse color covers cells and surrounding tissue without a discernible cellular pattern.	The result is difficult to assign to ASPH because HPA describes general cytoplasmic expression, while UniProt places the protein on intracellular membranes (HPA tissue IHC; UniProt Q12797 subcellular location). Check the negative reagent control and background-reduction steps (general IHC practice).
No staining is visible in an adipose section with identifiable adipocytes.	HPA reports high adipocyte staining in adipose tissue, so an absent signal warrants a technical check (HPA tissue IHC). Verify tissue preservation, the antibody’s IHC suitability, retrieval, detection, and controls using the chosen assay instructions (general IHC practice). HPA’s Uncertain IHC reliability prevents treating one negative section as decisive evidence of absence (HPA tissue IHC).

💡Expected ASPH appearanceCall a positive result when recognizable adipocytes or bronchial respiratory epithelial cells show predominantly cytoplasmic, ER-compatible staining, potentially strong where HPA reports High staining; isolated nuclear, extracellular, or indiscriminate background color is suspect (HPA tissue IHC; HPA subcellular ICC-IF; UniProt Q12797 subcellular location).

How each factor affects the staining
Antibody and tissue evidence	HPA rates the overall tissue IHC profile Uncertain; among its listed antibodies, HPA059303 has Uncertain IHC validation and HPA055161 has no listed IHC rating (HPA tissue IHC; HPA antibodies). Interpret a matching pattern with controls rather than treating it as independent target confirmation (general IHC practice).
Epitope location and access	ASPH has one transmembrane segment at residues 54–74, separating a short cytoplasmic region from a longer lumenal region (UniProt Q12797 topology). Epitope placement could affect how an antibody recognizes processed tissue, but no antibody epitope or ASPH-specific retrieval requirement is supplied; use the selected antibody’s validated IHC instructions (general IHC practice).
Isoform coverage	UniProt lists 11 ASPH isoforms; isoform 1 was detected across tested tissues, while isoform 8 has a more restricted reported distribution (UniProt Q12797 isoforms; UniProt Q12797 tissue specificity). Without an epitope map, a stain cannot be assumed to detect every isoform or explain a tissue difference by isoform alone.
Tissue and cell selection	HPA reports high staining in adipocytes, adrenal glandular cells, colon glandular cells, glia, and Purkinje cells, among others; it reports no staining in several specified cell populations (HPA tissue IHC). Score the named cell population, since a whole-organ label can conceal different cell-level results (general IHC practice).
IF/ICC Q: Where should a separate cell-imaging assay localize ASPH?	HPA reports enhanced ER localization by ICC-IF and lists enhanced ICC validation for both HPA antibodies (HPA subcellular ICC-IF; HPA antibodies). That supports an ER-pattern expectation in the separate IF/ICC guide; it does not supply an IHC retrieval setting or an IF/ICC protocol.

Why is my staining missing, weak or wrong?
Situation	Likely cause	Next action
Positive tissue has little or no chromogenic signal.	The assay may have insufficient antigen exposure, antibody binding, or detection; the slide alone cannot distinguish these possibilities (general IHC practice).	Check the antibody’s IHC instructions, retrieval and detection steps, and a known-positive control; adipocytes are an HPA high-staining reference, subject to its Uncertain IHC reliability (HPA tissue IHC; general IHC practice).
Negative reagent control also develops color.	Endogenous tissue activity or nonspecific detection-system binding can contribute color in chromogenic IHC (general IHC practice).	Apply the detection system’s appropriate blocking and control steps, then reassess whether color remains confined to the expected cell population (general IHC practice; HPA tissue IHC).
Color is uniform across the section or pools at tissue edges.	Broad background or uneven reagent coverage can obscure the cellular distribution (general IHC practice).	Review blocking, washes, reagent coverage, and detection exposure according to the assay instructions; judge the result only where cellular morphology and controls are interpretable (general IHC practice).
Predominantly nuclear or extracellular signal persists.	The distribution disagrees with ASPH’s reported intracellular membrane locations (UniProt Q12797 subcellular location).	Compare a negative reagent control and an HPA high-staining cell population, then reassess antibody suitability and detection conditions before scoring the signal as ASPH (HPA tissue IHC; general IHC practice).
Cardiomyocytes or skeletal myocytes stain strongly.	HPA lists both cell populations as not detected by tissue IHC; the mismatch may reflect background or antibody-specific recognition (HPA tissue IHC; general IHC practice).	Verify cell identity and morphology, inspect controls, and report the discrepancy rather than assigning it to an ASPH isoform without epitope evidence (UniProt Q12797 isoforms; general IHC practice).
Two antibodies yield different tissue patterns.	HPA’s tissue IHC reliability is Uncertain, and its listed antibodies do not share an enhanced IHC validation rating (HPA tissue IHC; HPA antibodies).	Compare staining in the same named cell types with matched controls and each antibody’s IHC instructions; describe discordance without declaring either pattern definitive (general IHC practice).

Source: UniProt Q12797 Human Protein Atlas tissue Human Protein Atlas subcellular

Experiment evidence

IHC & IF images showing ASPH staining

IHC analysis of ASPH using anti-ASPH antibody (PB9478). ASPH was detected in paraffin-embedded section of Human Mammary Cancer Tissue. Heat mediated antigen retrieval was performed in citrate buffer (pH6, epitope retrieval solution) for 20 mins. The tissue section was blocked with 10% goat serum. The tissue section was then incubated with 1μg/ml rabbit anti-ASPH Antibody (PB9478) overnight at 4°C. Biotinylated goat anti-rabbit IgG was used as secondary antibody and incubated for 30 minutes at 37°C. The tissue section was developed using Strepavidin-Biotin-Complex (SABC)(Catalog # SA1022) with DAB as the chromogen.

PB9478 · IHCIHC analysis of ASPH using anti-ASPH antibody (PB9478). ASPH was detected in paraffin-embedded section of Human Mammary Cancer Tissue. Heat

IHC analysis of ASPH using anti-ASPH antibody (PB9478). ASPH was detected in immunocytochemical section of A549 cell. Enzyme antigen retrieval was performed using IHC enzyme antigen retrieval reagent (AR0022) for 15 mins. The cells were blocked with 10% goat serum. And then incubated with 1μg/ml rabbit anti-ASPH Antibody ( PB9478) overnight at 4°C. Biotinylated goat anti-rabbit IgG was used as secondary antibody and incubated for 30 minutes at 37°C. The section was developed using Strepavidin-Biotin-Complex (SABC)(Catalog # SA1022) with DAB as the chromogen.

PB9478 · IHCIHC analysis of ASPH using anti-ASPH antibody (PB9478). ASPH was detected in immunocytochemical section of A549 cell. Enzyme antigen retriev

HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000198363-ASPH/tissue/cerebral+cortex#imid_16393615

HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000198363-ASPH/tissue/colon#imid_16411337

HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000198363-ASPH/tissue/liver#imid_16411463

HPA · PancreasHuman Protein Atlas IHC, Pancreas. Source: https://www.proteinatlas.org/ENSG00000198363-ASPH/tissue/pancreas#imid_16411395

HPA · ICC-IF HeLaHuman Protein Atlas immunofluorescence, HeLa, antibody HPA055161; green = ASPH, blue = nucleus, red = microtubules.

← swipe / scroll for more images →

Real IHC / IF data behind the staining-pattern expectations in this section.

Sample controls for ASPH IHC & IF

🧪Run adipose tissue first and look for staining in adipocytes (HPA: High in adipocytes); use heart muscle cardiomyocytes as the negative tissue (HPA: Not detected in cardiomyocytes). Within the adipose section, unstained non-adipocyte cells can serve as internal background comparators, showing counterstain without DAB signal, but their ASPH-negative status should not be assumed from the adipocyte result (HPA: High in adipocytes).

Positive control tissue: Adipose tissue (Adipocytes, HPA High)

Negative control tissue: Heart muscle (HPA Not detected)

ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show ASPH in HeLa, U2OS, A-549, BJ [Human fibroblast], with annotated localisation: Endoplasmic reticulum (enhanced) (HPA subcellular).

Technical controls: Include a no-primary (secondary-only) slide, a matched rabbit IgG control, and ASPH-knockout material as a biological negative (caption: rabbit anti-ASPH antibody; standard IHC practice). Block endogenous peroxidase and check for endogenous biotin signal when using the caption’s biotin–streptavidin/DAB detection system (caption: biotinylated secondary, streptavidin–biotin complex, DAB; standard IHC practice).

⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected PB9478 paraffin-section caption does not state the fixative (caption: fixative not stated). The caption reports citrate retrieval at pH 6 for 20 minutes; it supports that starting condition but does not establish whether ASPH staining depends on retrieval (caption: heat-mediated antigen retrieval). The supplied evidence does not establish that frozen sections or IF are easier than paraffin IHC; in adipose tissue, lipid extraction can leave narrow cytoplasmic rims that complicate scoring (standard histology practice), while HPA ICC-IF places ASPH in the endoplasmic reticulum (HPA: endoplasmic reticulum, enhanced).

HPA tissue IHC evidence for ASPH

Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Uncertain — Medium consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

Tissue	Cell type	Level	Evidence	Source
Adipose tissue	Adipocytes	High	Protein (IHC)	HPA →
Adrenal gland	Glandular cells	High	Protein (IHC)	HPA →
Breast	Adipocytes	High	Protein (IHC)	HPA →
Bronchus	Respiratory epithelial cells	High	Protein (IHC)	HPA →
Caudate	Glial cells	High	Protein (IHC)	HPA →

Undetected expression · recommended negative controls

Tissue	Cell type	Level	Evidence	Source
Heart muscle	Cardiomyocytes	Not detected	Protein (IHC)	HPA →
Liver	Cholangiocytes	Not detected	Protein (IHC)	HPA →
Lymph node	Germinal center cells	Not detected	Protein (IHC)	HPA →
Parathyroid gland	Glandular cells	Not detected	Protein (IHC)	HPA →
Skeletal muscle	Myocytes	Not detected	Protein (IHC)	HPA →

Section 3

Advanced ASPH IHC Tips

Troubleshoot ASPH staining in paraffin section IHC by checking retrieval, controls, cellular distribution, and scoring before interpreting differences between specimens.

How should I adjust retrieval when ASPH staining is weak in paraffin sections?

Start with heat mediated retrieval in citrate buffer at pH 6 for 20 minutes on paraffin sections (datasheet PB9478). Keep heating and cooling consistent across comparison slides, and inspect both staining and tissue integrity before changing conditions (standard IHC practice). ASPH spans the endoplasmic reticulum membrane at residues 54–74, with distinct cytoplasmic and lumenal regions, so epitope accessibility warrants attention (UniProt Q12797 topology). If staining remains weak, titrate retrieval time on adjacent sections before trying another buffer; hold antibody concentration at the documented 1 μg/mL while assessing that change (datasheet PB9478; standard IHC practice).

How can I troubleshoot ASPH differences between paraffin blocks with different fixation histories?

Record the fixative, fixation duration, processing history, and block age for each specimen before comparing ASPH staining (standard IHC practice). The PB9478 paraffin section caption does not state a fixative, so ASPH specific sensitivity to fixation remains unknown for this antibody (datasheet PB9478). Compare adjacent sections using the same citrate pH 6 retrieval for 20 minutes and the same detection workflow to limit procedural variation (datasheet PB9478; standard IHC practice). If fixation histories differ, include a similarly processed control tissue and interpret staining differences cautiously, especially when morphology or counterstaining also differs (standard IHC practice).

Which ASPH staining pattern should I expect in chromogenic tissue sections?

Look for predominantly cytoplasmic staining in tissue sections, consistent with the reported general IHC pattern (HPA: general cytoplasmic expression). ASPH is assigned to the endoplasmic reticulum and sarcoplasmic reticulum membranes; residues 1–53 face the cytoplasm and 75–758 face the lumen (UniProt Q12797 topology). At light microscope resolution, a granular or perinuclear cytoplasmic pattern can support an ER associated interpretation, but it cannot establish membrane sidedness (standard IHC interpretation; UniProt Q12797 topology). Evaluate the stained cell type and surrounding morphology rather than treating diffuse extracellular deposits or nuclear staining alone as convincing ASPH localisation (standard IHC practice).

Can this ASPH stain distinguish isoforms or reveal which side of the membrane is labeled?

Do not assign a chromogenic signal to one ASPH isoform without an antibody epitope and isoform cross reactivity map (UniProt Q12797: 11 isoforms; standard IHC interpretation). The full length protein has a cytoplasmic segment at residues 1–53, a membrane segment at 54–74, and a lumenal region at 75–758 (UniProt Q12797 topology). Reported glycosylation sites at 64, 452, and 706 could matter when evaluating a mapped epitope, but their effect on this antibody is undocumented (UniProt Q12797 glycosylation; datasheet PB9478). Use an epitope mapped reagent or isoform specific validation before making an isoform or membrane side claim (standard IHC practice).

How should I check an ASPH IHC pattern with multiplex immunofluorescence?

Use IF as a separate validation experiment and compare its cellular pattern with the chromogenic section, allowing for differences in specimen preparation (standard IF/IHC practice). Multiplex ASPH with a marker identifying the expected cell type, such as an adipocyte marker in adipose tissue, and include single stain controls (HPA: high in adipocytes; standard IF practice). Choose fluorophores after inspecting unstained tissue autofluorescence, favoring channels with clearer separation from that background (standard IF practice). If the antibody epitope maps to ASPH residues 1–53 or 75–758, optimise permeabilisation for cytoplasmic or ER lumen access respectively; its epitope is not supplied here (UniProt Q12797 topology; standard IF practice).

What should I change if ASPH DAB staining is widespread or granular?

First inspect a no primary control and the tissue morphology to distinguish detection background from cell associated staining (standard IHC practice). The documented workflow uses 10% goat serum blocking, 1 μg/mL primary antibody overnight at 4°C, a biotinylated secondary, and DAB development (datasheet PB9478). Optimise peroxidase blocking, washing, and DAB development as general chromogenic IHC steps; assess secondary only and endogenous biotin controls when using a biotin based system (standard IHC practice; datasheet PB9478). Judge residual signal against the expected cytoplasmic distribution and a matched control section, since HPA tissue staining has Uncertain reliability (HPA: general cytoplasmic expression; HPA: reliability Uncertain).

How should I quantify ASPH staining across tissues with mixed cell populations? ⚠ ANSWER MARKED FOR VERIFICATION

Define the cell population and compartment before scoring, because the reported tissue pattern is generally cytoplasmic and varies by cell type (HPA: general cytoplasmic expression; HPA tissue IHC). For a defined population, record percentage of positive cells and intensity using an H-score, then report the number of evaluable cells (standard IHC scoring practice). If counting discrete positive cells, express density per mm² of viable, annotated tissue and keep the positivity threshold fixed across slides (standard IHC quantification practice). Normalise comparisons to the same cell population, viable tissue area, staining batch, and control section; exclude necrosis and damaged edges consistently (standard IHC practice).

When should I doubt a positive ASPH IHC result?

A convincing result should align with cellular morphology and the reported general cytoplasmic pattern, rather than rely on DAB color alone (HPA: general cytoplasmic expression; standard IHC practice). Question isolated nuclear or extracellular staining, strong cut edge staining, and deposits in necrotic regions; compare each with a no primary control (standard IHC interpretation). Check endogenous peroxidase and, for the documented biotin based detection system, endogenous biotin before attributing granular signal to ASPH (standard IHC practice; datasheet PB9478). Use cell type as context: adipocytes and colon glandular cells are reported high, whereas cardiomyocytes are reported undetected, but HPA rates its tissue IHC reliability Uncertain (HPA tissue IHC).

Boster reagents

Best ASPH / Aspartyl/asparaginyl beta-hydroxylase IHC Antibodies

PB9478 has a human paraffin-section IHC figure (PB9478 image caption). Its application list includes ICC, and its listed reactivity covers human, mouse and rat (catalog: PB9478).

Real IHC data

Anti-Aspartate beta hydroxylase/ASPH Antibody ®

Cat # PB9478

View product →

PB9478 will render with an IHC figure from a human mammary cancer paraffin section (PB9478 image caption). PB9478 also lists ICC and human, mouse and rat reactivity; no IF figure is supplied (catalog: PB9478).

Which to pick: For tissue IHC, choose PB9478: its human paraffin-section figure used citrate retrieval at pH 6 for 20 minutes and 1 μg/ml primary antibody; the fixative is unreported (PB9478 image caption). For IF/ICC, PB9478 lists ICC at 0.5–1 μg/ml, but the supplied cell image uses chromogenic detection and provides no IF validation (catalog: PB9478; PB9478 cell image caption). For cross-species work, PB9478 lists mouse and rat reactivity, while its supplied tissue IHC figure documents human tissue only (catalog: PB9478; PB9478 image caption).

Each figure is that product's own IHC / IF validation image from its datasheet.

References

UniProt Consortium. UniProt entry Q12797 (ASPH_HUMAN, Aspartyl/asparaginyl beta-hydroxylase).
Human Protein Atlas. ASPH tissue IHC expression (reliability: Uncertain).
Human Protein Atlas. ASPH subcellular location (ICC-IF): Localized to the endoplasmic reticulum..
Human Protein Atlas. ASPH antibody validation summary (2 antibodies).
Aspartate β-hydroxylase Regulates Expression of Ly6 Genes. Journal of Cancer 2024 — PMC10861829.
Heterogeneous Response of Tumor Cell Lines to Inhibition of Aspartate β-hydroxylase. Journal of Cancer 2024 — PMC11134442.
Identification of critical genes associated with radiotherapy resistance in cervical cancer by bioinformatics. Frontiers in oncology 2022 — PMC9373049.
Characterization of the Relationship Between the Expression of Aspartate β-Hydroxylase and the Pathological Characteristics of Breast Cancer. Medical science monitor : international medical journal of experimental and clinical research 2020 — PMC7784592.
PubMed PMID:7821814 — UniProt-cited evidence.
PubMed PMID:8823296 — UniProt-cited evidence.
PubMed PMID:10974562 — UniProt-cited evidence.